Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
X4 Pharmaceuticals is a biopharmaceutical company focused on developing oral small-molecule therapies targeting the CXCR4 receptor to treat rare immune system disorders like WHIM syndrome and chronic neutropenia. Its flagship product, mavorixafor (XOLREMDI), is the first FDA-approved drug for WHIM syndrome, aiming to increase circulating immune cells. The company leverages proprietary IP, strategic licensing, and global partnerships to develop and commercialize its innovative treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.